Developer docs
API playgroundTry for free, no card

Search company profiles

Qnomx

Full company profile

uuid0002evv

Namestring
Qnomx
Legal namestring
Qnomx AG
Websiteurl
qnomx.ai
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Qnomx AG is a Basel-based, privately held company founded in 2023 that has developed a GenAI platform for interpretation and clinical reporting in NGS-based oncology diagnostics. The product consists of two integrated modules — Qnomx Insight, which performs structured variant-level interpretation by consolidating evidence from OncoKB, COSMIC, ClinVar, gnomAD, Ensembl VEP, UniProtKB/ProtVar, REVEL, ESM, and PubMed into patient-specific draft annotations with traceable reasoning — and Qnomx Report, which transforms those structured interpretations into configurable, multilingual, clinician-ready reports with agentic chat for live editing. The platform deploys on top of existing tertiary analysis pipelines (Sophia Genetics, QIAGEN/QCI, VarSome) without disturbing validated upstream processes, and is positioned for IVDR Class C and EU AI Act compliance with ISO 27001 certification already achieved and ISO 13485, IVDR-C, and MDR-I certifications in progress.

The company targets oncology diagnostic laboratories scaling NGS-based cancer testing, with named customers and evaluation partners including Vall d'Hebron Research Institute (Spain), Labor Becker MVZ (Germany), Praava (Bangladesh), and GenCell (Argentina). Qnomx generates revenue through enterprise software licensing on a subscription basis, sold via direct field sales and an Early Access Programme, and is pursuing an 18-24 month clinical performance study in pediatric oncology with Vall d'Hebron to support its regulatory pathway. Total disclosed funding to date is approximately €1.7M in pre-Seed (April 2025, lead Heal Capital) plus an earlier 2023 seed-class round, the entity was incubated by CGC Genomics, and headcount remains in the 1-10 range, indicating an early-commercial-stage company whose scaling is gated primarily by regulatory certification rather than demand.

Short descriptiontext

Qnomx AG is a Basel-based GenAI platform that automates variant interpretation and clinical report generation for NGS-based oncology diagnostic laboratories, integrating evidence from major clinical databases and deploying on top of existing tertiary analysis pipelines.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBasel, Switzerland
HQ citystring
Basel
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical NGS interpretation, oncology decision support, variant interpretation software, genomic clinical reporting, AI diagnostics platform
Industry3 codes
PRIMARYHLAAANAD
Molecular Tumor Boards & Clinical Interpretation Services
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAF
Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code1 code
  • Computer Systems Design and Related Services54151
SIC code1 code
  • Services-Prepackaged Software7372
Product category
Clinical Genomics Software
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Software Platform Licensing
TypeSubscription Recurring
Description

Qnomx generates revenue through software platform licensing to oncology diagnostic laboratories. The platform is offered as an integrated solution (Qnomx Insight for interpretation and Qnomx Report for reporting) that labs deploy within their existing workflows. Revenue appears to be subscription-based with enterprise licensing terms.

qnomx.ai
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Qnomx develops a GenAI platform for NGS-based cancer genome interpretation, consisting of two integrated modules. Qnomx Insight performs structured variant-level interpretation by consolidating evidence from leading clinical, population, and functional databases (OncoKB, COSMIC, ClinVar, gnomAD, Ensembl VEP, UniProtKB/ProtVar, REVEL, PubMed) into patient-specific draft annotations. Qnomx Report transforms these structured interpretations into standardized, clinician-ready clinical reports following lab-configurable content standards, supporting multilingual output and agentic chat editing. The platform is deployed on top of existing tertiary analysis pipelines and targets IVDR Class C and EU AI Act compliance.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Reduces expert workload per NGS case by up to 85%
+2 more records
Product overview1 text field

Qnomx is a GenAI platform for NGS-based cancer genome interpretation, consisting of two integrated modules: Qnomx Insight handles structured variant-level interpretation by consolidating evidence from multiple clinical databases (OncoKB, COSMIC, ClinVar, gnomAD, Ensembl VEP, UniProtKB/ProtVar, REVEL, PubMed) into patient-specific draft annotations, while Qnomx Report transforms these structured interpretations into clinician-ready clinical reports with configurable standards, multilingual support, and agentic chat editing capabilities. The platform operates after variant filtering and before clinical sign-off, reducing expert workload per NGS case by up to 85%.

Product and service2 records
1Qnomx Insight
CategoryGenomic Interpretation Software
Description

Structured variant-level interpretation module that consolidates evidence across leading clinical, population, and functional sources (OncoKB, COSMIC, ClinVar, gnomAD, Ensembl VEP, UniProtKB/ProtVar, REVEL, ESMP, PubMed) in the context of each patient. Filters and prioritises variants straight from VCF files, drafts patient-specific annotations from traceable evidence bases, and shows reasoning, confidence, and agreement across sources for reviewable variant-level annotations.

2Qnomx Report
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-09
Description

Barcelona-based research institute collaborating on an 18-24 month clinical performance study to evaluate Qnomx's AI-assisted summarization platform in pediatric oncology. Study launched March 2026.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Established NGS tertiary-analysis platform serving clinical genomics labs worldwide. Qnomx explicitly integrates with SOPHiA's stack as a value-added AI layer, so SOPHiA is both a partner and the most likely incumbent to internalize similar AI features.

TypeBroad incumbent
Description

Major provider of clinical genomics interpretation software (QCI) used by oncology labs. Like SOPHiA, QCI is a confirmed Qnomx integration partner and a credible threat if it ships first-party AI interpretation.

TypeDirect peer
Description

Clinical variant interpretation platform widely used by diagnostic labs, including in oncology. Overlaps directly with Qnomx Insight on variant annotation and clinical interpretation, though Qnomx adds GenAI-driven narrative generation.

TypeDirect peer
Description

AI-driven clinical genomics interpretation platform used in hereditary disease and oncology. Closest direct competitor in clinical interpretation software with a comparable hospital-lab go-to-market motion.

TypeDirect peer
Description

Clinical genomics decision-support platform for rare disease and cancer, selling into hospital labs. Comparable in customer segment, regulatory positioning, and emphasis on automated clinical interpretation.

6Tempus Labs
TypeBroad incumbent
Description

AI-driven precision medicine company with broad oncology focus, including NGS interpretation and clinical reporting. Much larger and broader than Qnomx, but addresses overlapping oncologist and lab-customer pain points.

TypeEmerging player
Description

AI platform for pathology diagnostics with regulated, evidence-driven positioning. Adjacent rather than directly overlapping (pathology vs. NGS), but a useful comp for AI-in-regulated-diagnostics go-to-market.

TypeEmerging player
Description

AI-for-clinical-research and diagnostics company with European roots and regulated-AI focus. Comparable in mission (AI applied to clinical decision-making) and in building evidence-grade products for hospitals and pharma.

TypeBroad incumbent
Description

Oncology diagnostics and precision medicine company using molecular profiling and AI to support treatment decisions. Broader scope than Qnomx but overlaps on AI-assisted oncology interpretation and reporting.

TypeBroad incumbent
Description

Industry-leading molecular genomics profiling and interpretation for oncology, owned by Roche. Sets the bar for evidence-based cancer variant interpretation and report generation that Qnomx must differentiate against.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration11 records

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Qnomx

Clinical Genomics Softwareqnomx.ai

Qnomx AG is a Basel-based GenAI platform that automates variant interpretation and clinical report generation for NGS-based oncology diagnostic laboratories, integrating evidence from major clinical databases and deploying on top of existing tertiary analysis pipelines.

What Qnomx does

Qnomx AG is a Basel-based, privately held company founded in 2023 that has developed a GenAI platform for interpretation and clinical reporting in NGS-based oncology diagnostics. The product consists of two integrated modules — Qnomx Insight, which performs structured variant-level interpretation by consolidating evidence from OncoKB, COSMIC, ClinVar, gnomAD, Ensembl VEP, UniProtKB/ProtVar, REVEL, ESM, and PubMed into patient-specific draft annotations with traceable reasoning — and Qnomx Report, which transforms those structured interpretations into configurable, multilingual, clinician-ready reports with agentic chat for live editing. The platform deploys on top of existing tertiary analysis pipelines (Sophia Genetics, QIAGEN/QCI, VarSome) without disturbing validated upstream processes, and is positioned for IVDR Class C and EU AI Act compliance with ISO 27001 certification already achieved and ISO 13485, IVDR-C, and MDR-I certifications in progress.

The company targets oncology diagnostic laboratories scaling NGS-based cancer testing, with named customers and evaluation partners including Vall d'Hebron Research Institute (Spain), Labor Becker MVZ (Germany), Praava (Bangladesh), and GenCell (Argentina). Qnomx generates revenue through enterprise software licensing on a subscription basis, sold via direct field sales and an Early Access Programme, and is pursuing an 18-24 month clinical performance study in pediatric oncology with Vall d'Hebron to support its regulatory pathway. Total disclosed funding to date is approximately €1.7M in pre-Seed (April 2025, lead Heal Capital) plus an earlier 2023 seed-class round, the entity was incubated by CGC Genomics, and headcount remains in the 1-10 range, indicating an early-commercial-stage company whose scaling is gated primarily by regulatory certification rather than demand.

Qnomx firmographics

Firmographics
Name
Qnomx
Legal name
Qnomx AG
Website
https://qnomx.ai
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
1–10 employees
Short description
Qnomx AG is a Basel-based GenAI platform that automates variant interpretation and clinical report generation for NGS-based oncology diagnostic laboratories, integrating evidence from major clinical databases and deploying on top of existing tertiary analysis pipelines.
Ownership category
akta.pro rank

Qnomx industry classification

Industry
Product category
Clinical Genomics Software
NAICS
Computer Systems Design and Related Services (54151)
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLAAANAD
Molecular Tumor Boards & Clinical Interpretation Services
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAF
Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Clinical NGS interpretation
  • Oncology decision support
  • Variant interpretation software
  • Genomic clinical reporting
  • AI diagnostics platform

Where Qnomx is headquartered

Location

Headquarters

HQ city
Basel
HQ country
Switzerland
HQ region
Europe

Offices1 record

Markets served

Qnomx business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

  1. Software Platform Licensing: Qnomx generates revenue through software platform licensing to oncology diagnostic laboratories. The platform is offered as an integrated solution (Qnomx Insight for interpretation and Qnomx Report for reporting) that labs deploy within their existing workflows. Revenue appears to be subscription-based with enterprise licensing terms.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Qnomx product offering

Product offering

Core offering

Qnomx develops a GenAI platform for NGS-based cancer genome interpretation, consisting of two integrated modules. Qnomx Insight performs structured variant-level interpretation by consolidating evidence from leading clinical, population, and functional databases (OncoKB, COSMIC, ClinVar, gnomAD, Ensembl VEP, UniProtKB/ProtVar, REVEL, PubMed) into patient-specific draft annotations. Qnomx Report transforms these structured interpretations into standardized, clinician-ready clinical reports following lab-configurable content standards, supporting multilingual output and agentic chat editing. The platform is deployed on top of existing tertiary analysis pipelines and targets IVDR Class C and EU AI Act compliance.

Product overview

Qnomx is a GenAI platform for NGS-based cancer genome interpretation, consisting of two integrated modules: Qnomx Insight handles structured variant-level interpretation by consolidating evidence from multiple clinical databases (OncoKB, COSMIC, ClinVar, gnomAD, Ensembl VEP, UniProtKB/ProtVar, REVEL, PubMed) into patient-specific draft annotations, while Qnomx Report transforms these structured interpretations into clinician-ready clinical reports with configurable standards, multilingual support, and agentic chat editing capabilities. The platform operates after variant filtering and before clinical sign-off, reducing expert workload per NGS case by up to 85%.

Differentiator

Problem solved

Functional benefit

Products and services

  • Qnomx Insight Structured variant-level interpretation module that consolidates evidence across leading clinical, population, and functional sources (OncoKB, COSMIC, ClinVar, gnomAD, Ensembl VEP, UniProtKB/ProtVar, REVEL, ESMP, PubMed) in the context of each patient. Filters and prioritises variants straight from VCF files, drafts patient-specific annotations from traceable evidence bases, and shows reasoning, confidence, and agreement across sources for reviewable variant-level annotations.
  • Qnomx Report

Quantifiable outcome

  • Reduces expert workload per NGS case by up to 85%
  • +2 more outcomes

Companies that use Qnomx

Customer profile

Named customers4 records

Segments1 record

Ideal customer profiles1 record

Qnomx technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration11 records

AI capability5 records

Feature4 records

Qnomx partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Vall d'Hebron Institute of ResearchcoreStrategic or Co-development Partner · 9 March 2026Barcelona-based research institute collaborating on an 18-24 month clinical performance study to evaluate Qnomx's AI-assisted summarization platform in pediatric oncology. Study launched March 2026.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Qnomx competitors and assessment

Company assessment

Broad incumbents

  • SOPHiA GENETICS: Established NGS tertiary-analysis platform serving clinical genomics labs worldwide. Qnomx explicitly integrates with SOPHiA's stack as a value-added AI layer, so SOPHiA is both a partner and the most likely incumbent to internalize similar AI features.
  • QIAGEN (Digital Insights / QCI): Major provider of clinical genomics interpretation software (QCI) used by oncology labs. Like SOPHiA, QCI is a confirmed Qnomx integration partner and a credible threat if it ships first-party AI interpretation.
  • Tempus Labs: AI-driven precision medicine company with broad oncology focus, including NGS interpretation and clinical reporting. Much larger and broader than Qnomx, but addresses overlapping oncologist and lab-customer pain points.
  • Caris Life Sciences: Oncology diagnostics and precision medicine company using molecular profiling and AI to support treatment decisions. Broader scope than Qnomx but overlaps on AI-assisted oncology interpretation and reporting.
  • Foundation Medicine (Roche): Industry-leading molecular genomics profiling and interpretation for oncology, owned by Roche. Sets the bar for evidence-based cancer variant interpretation and report generation that Qnomx must differentiate against.

Direct peers

  • Saphetor (VarSome): Clinical variant interpretation platform widely used by diagnostic labs, including in oncology. Overlaps directly with Qnomx Insight on variant annotation and clinical interpretation, though Qnomx adds GenAI-driven narrative generation.
  • Fabric Genomics: AI-driven clinical genomics interpretation platform used in hereditary disease and oncology. Closest direct competitor in clinical interpretation software with a comparable hospital-lab go-to-market motion.
  • Congenica: Clinical genomics decision-support platform for rare disease and cancer, selling into hospital labs. Comparable in customer segment, regulatory positioning, and emphasis on automated clinical interpretation.

Emerging players

  • PathAI: AI platform for pathology diagnostics with regulated, evidence-driven positioning. Adjacent rather than directly overlapping (pathology vs. NGS), but a useful comp for AI-in-regulated-diagnostics go-to-market.
  • Owkin: AI-for-clinical-research and diagnostics company with European roots and regulated-AI focus. Comparable in mission (AI applied to clinical decision-making) and in building evidence-grade products for hospitals and pharma.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Qnomx social profiles

Digital presence

Qnomx compliance and trust

Trust signal

Compliance7 records

Qnomx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Qnomx leadership team

Management profile

Number of profiles

Profiles4 records

Qnomx funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Qnomx M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Qnomx

What does Qnomx do?

Qnomx develops a GenAI platform for NGS-based cancer genome interpretation, consisting of two integrated modules. Qnomx Insight performs structured variant-level interpretation by consolidating evidence from leading clinical, population, and functional databases (OncoKB, COSMIC, ClinVar, gnomAD, Ensembl VEP, UniProtKB/ProtVar, REVEL, PubMed) into patient-specific draft annotations. Qnomx Report transforms these structured interpretations into standardized, clinician-ready clinical reports following lab-configurable content standards, supporting multilingual output and agentic chat editing. The platform is deployed on top of existing tertiary analysis pipelines and targets IVDR Class C and EU AI Act compliance.

Is Qnomx a public or private company?

Qnomx is a private company. It is classified as venture growth investor backed and is currently operating.

When was Qnomx founded?

Qnomx was founded in 2023. It employs 1 to 10 people.

Where is Qnomx based?

Qnomx is headquartered in Basel, Switzerland, in the Europe region.

How does Qnomx make money?

One revenue line is on record: software Platform Licensing.

Who are Qnomx's main competitors?

Broad incumbents on record are SOPHiA GENETICS, QIAGEN (Digital Insights / QCI), Tempus Labs, Caris Life Sciences and Foundation Medicine (Roche). Direct peers are Saphetor (VarSome), Fabric Genomics and Congenica. Emerging players are PathAI and Owkin.

Does Qnomx have an API?

No public API is recorded for Qnomx.

What industry is Qnomx in?

Qnomx's product category is Clinical Genomics Software. Its primary akta.pro industry code is HLAAANAD, Molecular Tumor Boards & Clinical Interpretation Services, with a secondary code of HLAGAJAD, Bioinformatics & Multi-omics Analysis Software. Its NAICS code is 54151 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals